Organize:
- INCLIVA Biomedical Research Institute.
- ERI Biotecmed, University of Valencia.

Registration:
- Free registration through the following link: https://goo.gl/forms/TzzRMa7gQmGQt3er2
- Capacity up to 104 people

Meeting website:
http://www.incliva.es/formacion/jornadas/first-spanish-meeting-on-oligonucleotide-therapeutics-(smot1)
AGENDA
First Spanish Meeting on Oligonucleotide Therapeutics (SMOT1)

MEETING DIRECTORS:
• Dr. Beatriz Llamusi. University of Valencia, Department of Genetics.
• Dr. Ruben Artero. University of Valencia, Department of Genetics

OPENING. 08:45 – 09:00 am.
SESSION I. 09:00 – 11:00 am.
“Oligonucleotide synthesis and chemical modifications”
• “Historical perspective on oligonucleotide synthesis”. Dr. Ramón Eritja. IQAC, Barcelona.
• “Tools and techniques to assess quality of therapeutic nucleic acids (TNAs)”. Dr. Philipp Hadwiger. Axolabs, LGC.
• “Aptamers against MNK in the treatment of breast cancer”. Dr. Celia Pinto. IRyCIS-hospital, Madrid.
• “A lesson learned from a virus: The Viromer® Delivery Technology”. Dr. Christian Reinsch, Head of Development at Lypocalix.

COFFEE BREAK. 11:00 – 11:30 am.
SESSION II. 11:30 am – 02:00 pm.
“Preclinical studies”
• “Derepressing muscleblind expression by miRNA inhibitors ameliorates Myotonic Dystrophy-like phenotypes”. Dr. Beatriz Llamusi, University of Valencia.
• “Peptide enhanced delivery of oligonucleotides to the skeletal muscle and CNS”. Dr. Suzan Hammond. University of Oxford.
• “Innovative therapeutic approaches to chronic kidney disease”. Dr. Laura Garcia, IRyCIS, Madrid.
• “Cancer treatment using antisense oligonucleotides to regulate splicing”. Dr. Jordi Hernández, CRG, Barcelona.

LUNCH BREAK. 02:00 - 03:00 pm.
SESSION III. 03.00 – 05.30 pm.
“Clinical studies”
• “Preclinical and clinical studies using oligonucleotide therapies in Duchenne”. Dr. Virginia Arechavalagomeza, Instituto Biocruces, Bilbao.
• “Small activating RNA (saRNA) therapeutics – pre-clinical and early clinical experience.”. Dr. David Blakey, CEO at Mina Therapeutics.
• “Topical therapies based on siRNA for ocular diseases”. Dra. Tamara Martínez, Senior Researcher Sylentis.
• “Regulatory advice on oligonucleotide-based therapy regulation”. Lidia Cánovas. CEO at ASPHALION.
• “Oligonucleotides in the current therapeutic scenario. Critical analysis”. Dr. Joaquín Sáez, European correspondent of the European clinical research infrastructure network (ECRIN) in Spain.

PARTNERSHIPS:

[Logos of partners OTS, LGC, ASPHALION]